AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Sequence A extension spherical to develop their drug candidate AC01.
The financing was co-led by Novo Holdings, Pureos Bioventures, and Sound Bioventures. Current traders Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström additionally participated.
This funding will propel AnaCardio’s flagship drug candidate, AC01, by essential scientific trials focusing on coronary heart failure with diminished ejection fraction (HFrEF).
AnaCardio’s CEO Patrik Strömberg commented, “This can be a landmark day for AnaCardio, the place we report a major financing spherical, welcome three outstanding new traders, and announce the optimistic consequence of the primary research with AC01 in sufferers. We now have the info and funding to speed up the additional scientific growth of our first-in-class inotrope to enhance the lives of sufferers with coronary heart failure”.
AnaCardio was based in 2017 by Lars Lund, it’s a privately held Swedish scientific stage biopharmaceutical firm growing novel medication to deal with coronary heart failure. It was based primarily based on analysis from Karolinska Institutet displaying improved contractility of the center muscle by a novel and differentiated mechanism.
AC01, the corporate’s lead candidate, is a first-in-class oral ghrelin receptor agonist designed to reinforce cardiac contractility. In contrast to conventional inotropes, AC01 has proven potential to enhance coronary heart operate with out hostile results generally related to current therapies, comparable to tachycardia or hypotension.
The newly raised funds will assist the completion of the part 1b/2a GOAL-HF1 research, which features a 28-day cohort growth deliberate for early 2025. The research’s earlier findings revealed AC01’s security and efficacy, demonstrating its capability to reinforce cardiac contractility whereas sustaining a beneficial security profile. These outcomes are hailed as a breakthrough in coronary heart failure therapies by AnaCardio.
“The research outcomes reveal that AC01 is a promising novel inotrope displaying indicators of elevated contractility with out hostile results, comparable to tachycardia, arrhythmias, ischemia or hypotension that are sometimes seen with standard inotropes when administered to sufferers with coronary heart failure. AC01 proved to be well-tolerated and confirmed convincing goal engagement meriting development to the following growth stage testing the drug for 28 days to determine proof-of-concept and allow progress to late-stage scientific growth”, commented Professor Lars Lund, CSO and Founding father of AnaCardio.
Becoming a member of AnaCardio’s Board of Administrators are Johan Kördel (Sound Bioventures), Jørgen Søberg Petersen (Novo Holdings), and Veronica Gambillara Fonck (Pureos Bioventures). Moreover, Viktor Drvota, CEO of Karolinska Improvement, will substitute Per Aniansson, and Karin Hehenberger, Advisor at 3BFuture Well being, will transition to a board observer position.
“Coronary heart failure with diminished ejection fraction stays a serious unmet medical want, affecting thousands and thousands of lives worldwide. We’re thrilled to be a part of this groundbreaking initiative and proud to assist the event of a brand new therapeutic possibility that has the potential to considerably enhance outcomes for sufferers dealing with this difficult situation,” stated Johan Kördel, Managing Companion, Sound Bioventures.
